Blood Samples to Evaluate Biomarkers of Donor Chimerism
Study Details
Study Description
Brief Summary
We are interested in patient-specific factors that may affect the balance of recipient cells and donor cells in patients who receive stem cell transplants. We will look at the way the patient's body breaks down two drugs, fludarabine and mycophenolate mofetil, and how these two drugs affect the patient's body.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Donor T-cell chimerism [Day 28 post-transplant]
Secondary Outcome Measures
- Exposure to fludarabine and mycophenolate mofetil and their breakdown products. [Before and after transplant]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosed with a hematologic disease or malignancy
-
Scheduled to receive nonablative conditioning with fludarabine and total body irradiation
-
Donor is well-matched by high resolution DNA techniques.
-
Scheduled to receive postgrafting immunosuppression of oral MMF (CellCept) and an oral calcineurin inhibitor.
-
Age >18 years at the time of enrollment.
Exclusion criteria:
-Diagnosed with an immunodeficiency disorder
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Fred Hutchinson Cancer Research Center | Seattle | Washington | United States | 98109 |
Sponsors and Collaborators
- Fred Hutchinson Cancer Center
- National Heart, Lung, and Blood Institute (NHLBI)
Investigators
- Principal Investigator: Jeannine S McCune, PharmD, Fred Hutchinson Cancer Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FHCRC - 1980.00
- R01HL091744
- IR-5957